Diabetes drug shows promise against deadly brain tumors
NCT ID NCT07541781
First seen May 01, 2026 · Last updated Jun 12, 2026 · Updated 12 times
Summary
This early-phase trial tests whether sitagliptin, a common diabetes medicine, can help treat a severe type of brain cancer (grade 4 glioma) that has returned after standard treatment. About 45 adults will receive sitagliptin along with the standard drug bevacizumab. The study aims to find the safest dose and check if the combination reduces certain immune cells that may help the tumor grow.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
University of Iowa Health Care
Iowa City, Iowa, 52242, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.